Chief Physician of Melanoma and Sarcoma, Doctor of Medicine. Long-term engagement in pharmacotherapy for malignant melanoma, sarcoma, renal cell carcinoma, and urothelial carcinoma, with a primary focus on clinical research of novel drugs and translational research in melanoma. Obtained a Doctorate in Oncology from Peking University in 2011, and undertook a visiting study at the Melanoma Institute Australia (MIA) and Westmead Hospital in Sydney in 2012. As a key participant in clinical research, facilitated the approval and market launch of multiple new drugs, with several innovative treatment regimens incorporated into domestic and international diagnostic and treatment guidelines. Recent major research, such as the CAP 03-NEO triple-drug neoadjuvant therapy for acral melanoma, has gained international recognition, with related findings presented as an oral report at the 2025 ASCO Annual Meeting. Currently serves as Secretary of the Melanoma Quality Control Expert Committee of the National Cancer Quality Control Center, Standing Committee Member of the Melanoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO), and Member of the Sarcoma Expert Committee of CSCO. As a contributing author, participated in compiling the "Melanoma Diagnosis and Treatment Guidelines" of the National Health Commission, the "Melanoma Diagnosis and Treatment Guidelines" of CSCO, and the "China Integrated Cancer Diagnosis and Treatment Guidelines (Melanoma)" of the Chinese Anti-Cancer Association. Edited the CSCO Patient Education Handbook on Melanoma, promoting standardized cancer diagnosis and treatment, and providing precision medical services to patients.